Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
| Accumulated other comprehensive (loss) gain | (1,623) | 1,136 |
| Retained earnings | 80,095 | 24,163 |
| Total stockholders’ equity | 1,276,729 | 1,219,560 |
| Total liabilities and stockholders’ equity | $1,396,967 | $1,333,794 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s AOCI?
- Krystal Biotech, Inc. (KRYS) reported AOCI of -$1.62M in Q1 2026.
- How has Krystal Biotech, Inc.'s AOCI changed year-over-year?
- Krystal Biotech, Inc.'s AOCI decreased by 516.2% year-over-year, from $390K to -$1.62M.
- What is the long-term trend for Krystal Biotech, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s AOCI has grown at a 185.4% compound annual growth rate (CAGR), from $6K to $1.14M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Krystal Biotech, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude